Premium
O4‐01‐04: POLYMORPHISM AND TOXIC INTERACTIONS BETWEEN SOLUBLE AMYLOID OLIGOMERS AND TAU
Author(s) -
Kayed Rakez
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4743
Subject(s) - tauopathy , progressive supranuclear palsy , tau protein , neurodegeneration , protein aggregation , amyloid (mycology) , disease , dementia , biology , in vivo , dementia with lewy bodies , lewy body , chemistry , microbiology and biotechnology , alzheimer's disease , medicine , genetics , pathology
highlights the contrasting utility of small molecule inhibitors and capping peptides, and suggests specific roles for each. Capping inhibitors showed a narrower window of seeding inhibition, suggesting a higher degree of specificity. Patterns of sensitivity to the panel of capping inhibitors were diagnostic to the parent fibril polymorphs that were used for seeding, and the tauopathies from which they derived. Owing to a narrower window of activity, capping inhibitors may be powerful diagnostic tools and targeted inhibitors of proteopathic seeding by tau. On the other hand, small molecules tested here showed great promise as there was little variability in the range of seeding inhibition that was observed across different tauopathies that we tested.